



CV (CURRICULUM VITAE)

NAILYA RAFAELEVNA BULATOVA

Professor of Pharmacology & Therapeutics

School of Pharmacy/The University of Jordan

Amman, Jordan

Personal Information

Name: Nailya Rafaelevna Bulatova
Date of Birth: 21, April, 1961
Nationality: Jordanian
Current Amman, Jordan
Address: Tel: +962 799377784
Email: nyounes@ju.edu.jo

Education	
1978-1984	Medical Doctor (Diploma with Honors). Bashkirian Medical Institute, Faculty of Medicine, USSR (Russia), Ufa, 450000, Lenina st., 2.
1986-1989	Ph.D. in Medicine (Pharmacology) (Degree Excellent), <i>Thesis title:</i> "Effect of methyluracyl, oxymethacyl, tuftsin & heptapeptide on mononuclear phagocytes & brain synaptosomal membranes in stress". Scientific-Research Institute of Pharmacology, Academy of Medical Science, Moscow, USSR (Russia), 125315, Moscow, Baltiyskaya st., 8.
Training and Working Experience	
Sep 1984- Aug 1986	Teaching & Research Assistant in Pharmacology, Department of Pharmacology, Faculty of Medicine, Bashkir Medical Institute, Ufa, Russia.
Sep 1986- Oct 1989	Ph.D. student, Scientific-Research Institute of Pharmacology, Academy of Medical Science, Moscow, USSR (Russia), 125315, Moscow.
Sep 1992- Sep 1994	Lecturer of Pharmacology, Department of Pharmacology, Faculty of Medicine, University of Tripoli, Libya.
Oct 1995- Jun 1996	Lecturer of Pharmacology, Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
1996-2000	Assistant Professor of Pharmacology, Faculty of Pharmacy, Al-Isra University, Amman, Jordan.
2000-2001	Lecturer of Pharmacology & Therapeutics, Department of Biopharmaceutics & Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman, Jordan.
2001-2007	Assistant Professor of Pharmacology & Therapeutics, Department of Biopharmaceutics & Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan.
2007- 2012	Associate Professor of Pharmacology & Therapeutics, Department of Biopharmaceutics & Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan.
2009- 2010	Associate Professor of Pharmacology & Therapeutics, Department of Clinical Pharmacy, Faculty of Pharmacy, The Applied Sciences Private University, Amman, Jordan (sabb. leave)
Nov 2012- till now	Professor of Pharmacology & Therapeutics, Department of Biopharmaceutics & Clinical Pharmacy, School of Pharmacy, The University of Jordan.
Sep 2013- Jun 2014	Professor of Pharmacology & Therapeutics, Department of Pharmaceutical Sciences, Faculty of Pharmacy, Al Ahliyya Amman University, Amman, Jordan (sabb. leave)
Sep 2014- Sep 2016	Chair, Department of Biopharmaceutics & Clinical Pharmacy, School of Pharmacy, The University of Jordan.
Sep 2016- Sep 2018	Vice-Dean, School of Pharmacy, The University of Jordan.

Research Interests

1. Relation between diabetes, cardiovascular disease and inflammation
2. Medications and driving
3. Use of herbal medications in pregnancy
4. Drug abuse and misuse
5. Pharmacogenetics (genetic polymorphism of drug metabolizing enzymes, transporters and disease markers in Jordanian population and their impact on pharmacotherapy)
6. Reversal of efflux-mediated resistance in fungal cells
7. Hypertension management in specific population (diabetic, renal transplant)
8. Development of medication therapy management in Jordan
9. Development of healthcare education
10. Study of antiplatelet activity of drugs
11. Anti-aging research
12. Management of renal transplant patients

Research Funding/Grants

- | | |
|------------------|---|
| Feb, 2002 | 1. Study of multidrug resistance in bacteria. (Deanship of Academic Research, The University of Jordan, 4, 000 JD). Publication no.24. |
| May, 2004 | 2. Rational drug use in Jordan. (Deanship of Academic Research, The University of Jordan, 4, 000 JD). Publications no. 21-23, 25, 26,27,31. |
| May, 2005 | 3. Development of Pharmaceutical Care in Jordan. (Deanship of Academic Research, The University of Jordan, 4, 000 JD). Publications no.21,22,24,27,31,34-36. |
| Jan, 2006 | 4. Improvement of management of allergic rhinitis in Jordan. (Deanship of Academic Research, The University of Jordan, 20, 000 JD). Publications no. 28,29,32,33. |
| Mar, 2007 | 5. Study of genetic polymorphism in Jordanian population (Deanship of Academic Research, The University of |

Jordan, **4, 000 JD**). Publication no. 37.

- May, 2008** 6. Trends in blood pressure control in different categories of hypertensive patients in Jordan. (Deanship of Academic Research, The University of Jordan, **sponsored sabbatical leave**). Publications no. 36&40.
- May, 2009** 7. Comprehensive medication management review in Jordan (Deanship of Academic Research, The Applied Sciences Private University, Amman, Jordan, **4,900 JD**). Publications no. 38-39.
- 2011** 8. The effects of metformin on inflammatory markers in obese type 2 diabetes mellitus Jordanian patients. (Deanship of Academic Research, The University of Jordan, **27, 400 JD**).
- 2011** 9. Study of mechanisms of reversal of fluconazole resistance by chemosensitizers. (Deanship of Academic Research, The University of Jordan. **10, 000 JD**). Ongoing.
- 2012** 10. Study of prevalence and risk factors associated with diabetic foot infections caused by MRSA among Jordanian patients, (Deanship of Academic Research, The University of Jordan **20, 600 JD**). Ongoing.
- 2013** 11. Use of Herbal Remedies During Pregnancy Among Jordanian Women (Deanship of Academic Research, The University of Jordan 3, 500 JD).
- 2013** 12. Patients' knowledge, attitude and practice regarding use of driving impairing medicines in Jordan. (Deanship of Academic Research, The University of Jordan, **sponsored sabbatical leave**).
- 2013** 13. The relationship between urinary megalin levels and vitamin D deficiency in patients with diabetes mellitus, and the effect of vitamin D supplement on urinary megalin-
- 2013** a. A grant of Deanship of Academic Research/The University of Jordan (**10, 000 JD**) and;
- b. Scientific Research Fund-SRF/Ministry of Higher Education (**submitted full proposal 37, 000 JD claim**). Ongoing.
14. The association between blood oxytocin levels and insulin

- sensitivity in patients with pre-diabetes and type 2 diabetes mellitus and the evaluation of the cardioprotective [antiobesity, antidiabetes, anti-inflammatory, antioxidative and anti-atherogenic] effects of oxytocin in animal models of obesity and diabetes: Scientific Research Fund-SRF/Ministry of Higher Education (**89, 000 JD claim**). Ongoing.
- 2015**
15. Study of salivary biomarkers in metabolic syndrome and diabetes mellitus patients. Deanship of Academic Research, The University of Jordan (**10, 000 JD**). Ongoing.
- March**
- 2017**
16. Study of the prevalence of QTc prolongation induced by psychotropic medications among Jordanians: a cross-sectional study. . Deanship of Academic Research, The University of Jordan (**5, 000 JD**). Ongoing.

Awards

1. The University of Jordan Award of Best Researcher, Academic Year 2010-2011.

Publications

1. **Bulatova NR**, Tolstikov GA, Lerman BM, Belogaeva TA (1985). The effect of pyrimidine and adamantyl derivatives on the primary immune response. In: Actual Problems of Physiology, Biochemistry and Pharmacology of Functional System. Ufa: 33-35.
2. Mineeva MF, **Bulatova NR** (1988). Tyrosine hydroxylase of leukocytes and macrophages and the effect of pharmacological substances on its properties In: Pharmacology and Scientific- Technical progress. Tashkent: 249.
3. Avdulov NA, Eremenko AV, **Bulatova NR**, *et. al.* (1988). Multiprobe method of study of structure rebuilding in biomembranes. In: Luminescent Analysis in Medicine and Biology and its Apparatus Supplementation. Riga: 40-41.
4. **Bulatova NR** (1988). Functional activity of rat macrophages in chronic psychogenic stress and its correction with peptides of tuftsin group. In: Neostimulators. Chita: 32-33.

5. **Bulatova NR (1989)**. The effect of pyrimidine derivatives, peptides of tuftsin group & phosphobenzide on functional state and structural characteristics of rat macrophage membranes in chronic psychogenic stress. Printed as manuscript and deposited at the All-Union Institute of Scientific and Technical Information on 09.01.1989 for N 186-889: 26 P.
6. **Bulatova NR**, Krinskaya AV, Valdman AV (1989). The study of the effect of chronic psychogenic influence on mononuclear phagocyte state. In: Clinical and Laboratory Characteristics of Phagocyte Reactions. Gorky: 40-44.
7. **Bulatova NR**, Romanova EA, Krinskaya AV, *et. al* (1989). The poststressor correction of macrophage functional activity by tuftsin and its derivatives. The Bulletin of Experimental Biology and Medicine, **7**: 64-67.
8. Shigaev NI, **Bulatova NR (1990)**. The effect of dopaminergic drugs on humoral immunity. In: Fundamental Science for Public Health. Ufa: 65.
9. Mineeva MF, **Bulatova NR**, Valdman AV (1990). The effect of tuftsin and oxymethacil on macrophage tyrosine hydroxylase activity in chronic stress. The Bulletin of Experimental Biology and Medicine, **4**: 327-330.
10. **Bulatova NR**. Kinskaya AV, Valdman AV (1990). Poststressor correction of rat mononuclear phagocyte function by tuftsin and its derivatives. In: Factors of Cellular and Humoral Immunity in Various Physiological and Pathological States. Chelyabinsk: 170.
11. **Bulatova NR**, Krinskaya AV, Losev AV, Valdman AV (1990). The effect of plasma lipid composition on rat mononuclear functional activity in experimental neurosis. Ibid: 171.
12. Lazareva DA, Tolstikov GA, Alekhin EK, Plechev VV, Sarmanaev SK, **Bulatova NR (1990)**. Immune-modulating and antistress properties of oxymethacil. European Journal of Pharmacology, **183(3)**: 914-915.
13. Avdulov NA, Eremenko AV, Valdman AV, Malin KM, **Bulatova NR**, *et. al* (1990). Changes in synaptosomal membranes from cerebral cortex due to psychogenic stress in rats. Ann Inst Super Sanita (Italy), **26(1)**: 31-36.
14. **B(o)ulatova NR**, Qato MK, Ibrahim ZZ (1999). Effect of plants used in Arabic folkloric medicine on blood glucose, cholesterol and triglycerides levels in diabetic mice. FASEB, **13(4)**: A233.

15. Mohammed FA, **B(o)ulatova N (2000)**. Topical Oleo-Hydrogel Preparations of Piroxicam with Enhanced Skin Permeability and Antiinflammatory Activity. *Zagazig J Pharm Sci*, **9(2)**: 20-25.
16. Maarouf AR, Qato MK, **B(o)ulatova N**, El-Naddaf AR **(2001)**. Synthesis, analgesic and anti-inflammatory activities of certain thiazole, thiadiazole and triazole derivatives of ibuprofen. *Alex J Pharm Sci*, **15(1)**: 77- 81.
17. Ibraheim ZZ, **B(o)ulatova N**, Qato M **(2001)**. Effects of Some Plants Used in Arabic Traditional Medicine on Blood Glucose, Cholesterol and Triglycerides Levels of Normal and Streptozotocin-Hyperglycemic Mice. *Bull. Pharm. Sci., Assiut University*. – 2001, **24(2)**: 271-277.
18. Ibrahim ZZ, Phaily SS, **B(o)ulatova N (2001)**. Phytochemical and Pharmacological Studies of *Ferula hermonis* Grown in Syria. In: Abstracts of the 5th Scientific Congress of the Association of the Colleges of Pharmacy in the Arab World & the 2nd International Conference of the Faculty of Pharmacy (Amman, October 16-18, 2001).
19. Ibraheim ZZ, **B(o)ulatova NR (2002)**. Studies of the Anti-inflammatory Properties of Parsley, Dill, and Thyme in Mice. In: Proceedings of the Assiut University Third Pharmaceutical Sciences Conference (Assiut, March 5-6, 2002).
20. Otoom S, Nuseir M, Hasan M, Hadidi H, Samawi R, Younes AM, Darweesh M, **B(o)ulatova N (2003)**. Association of Polycystic Ovaries with the Use of Valproic Acid in Jordanian Epileptic Patients. *Clin Drug Invest*, **23(8)**: 527-532.
21. Aburuz S, **Bulatova NR**, Yousef AM **(2006)**. Validation of a Comprehensive Treatment Related Problems Assessment and Classification Tool. *Pharmacy World & Science*, **28(4)**: 222-32.
22. **Bulatova NR**, Aburuz S, Yousef AM **(2007)**. An Innovative Pharmaceutical Care Practical Course. *Advances in Health Sciences Education*, **12**: 211-222.
23. **Bulatova NR**, Yousef AM, Aburuz S **(2007)**. Antiplatelet Therapy for Primary and Secondary Prevention in Jordanian Patients with Diabetes Mellitus. *Thrombosis Research*, **121**: 43-50.
24. **Bulatova NR**, Darwish RM **(2008)**. Effect of Chemosensitizers on Fluconazole Activity against *Candida albicans*. *Medical Principles and Practice*, **17**: 117-121.
25. Yousef AM, **Bulatova NR**, Aburuz S **(2008)**. Management of Coronary Artery Disease in Jordan: Cross-Sectional Comparative Study. *Jordan Journal of*

Pharmaceutical Sciences, **1(1)**: 28-39.

26. Akl KF, **Bulatova N**, Yousef A-M (2008). Recurrent ecchymoses after acute tacrolimus intoxication. *Pediatric Nephrology*, **23**: 2101.
27. Yousef A-M, Arafat T, **Bulatova NR**, Al-Zumyly R (2008). Smoking behavior modulates pharmacokinetics of orally administered clopidogrel. *Journal of Clinical Pharmacy and Therapeutics*, **33**: 439–449.
28. Aburuz S, **Bulatova N**, Tawalbeh M, Gazawi M (2009). The Validity and Reliability of the Arabic Version of the EQ-5D: a Study from Jordan. *Annals of Saudi Medicine*, **29 (4)**: 304-308.
29. Aburuz S, **Bulatova N**, Tawalbeh M, Zahran F (2009). Development and Validation of the Arabic Allergic Rhinitis Quality of Life Questionnaire. *Saudi Medical Journal*, **30 (12)**: 1577-83.
30. Kasabri V, **Bulatova N** (2010). Current View on Biology of Aging. *Jordan Medical Journal*, **44 (2)**: 181-192.
31. **Bulatova N**, Yousef A-M, Al-Khayyat G, Qosa H (2011). Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors. *Current Drug Safety*, **6(1)**: 3-11.
32. Aburuz S, **Bulatova N**, Tawalbeh M (2011). Skin prick test reactivity to aeroallergens in Jordanian allergic rhinitis patients. *Eastern Mediterranean Region Health Journal*, **17(7)**: 604-610.
33. Tawalbeh M, **Bulatova N**, Aburuz S (2011). Investigation of the impact of aeroallergens sensitization on allergic rhinitis severity. *Jordan Medical Journal*, **45(1)**:18-28.
34. AbuRuz SM, **Bulatova NR**, Yousef A-M, Al-Ghazawi MA, Alawwa IA, Al-Saleh A (2011). Comprehensive assessment of treatment related problems in hospitalized medicine patients in Jordan. *Int J Clin Pharm*, **33(3)**: 501-11.
35. AbuRuz SM, Al-Ghazawi MA, **Bulatova N**, Jarab AS, Alawwa IA, Al-Saleh A (2012). Expectations and Experiences of Physicians Regarding Pharmaceutical Care and the Expanding Role of Pharmacists in Jordan. *Jordan Journal of Pharmaceutical Sciences*, **5(1)**: 74-86.

36. **Bulatova N**, Yousef AM, Qusa H, Al Khayat G, Ailabouni W, Wahbeh A, Al-Ulema M (2012). Management of hypertension and factors affecting its control in Jordanian renal transplant recipients. *International Journal of Clinical Pharmacy*, **34(3)**: 439-44.
38. Qunaibi E, Basheti IA, Hamadi SA, **Bulatova NR**, Shanah A, Abu-Gharbieh E. (2013). Effect of Divergence in Patients' Socioeconomic Background on their Perspective of the Role of the Community Pharmacist in Amman, Jordan. *Tropical Journal of Pharmaceutical Research*, **12 (2)**: 247-253.
39. Basheti IA, Qunaibi EA, **Bulatova NR**, Samara S, Aburuz S (2013). Treatment related problems for outpatients with chronic diseases in Jordan: the value of home medication reviews. *International Journal of Clinical Pharmacy*, **35(1)**: 92-100.
40. **Bulatova NR**, Yousef A-M, AbuRuz S, Abu Farha R (2013). Hypertension Management and Factors Associated with Blood Pressure Control in Jordanian Patients Attending Cardiology Clinic. *Tropical Journal of Pharmaceutical Research*, **12 (5)**: 000-000.
41. Basheti IA, Qunaibi EA, AbuRuz S, Samara S, **Bulatova NR** (2013). Home Medication Reviews In a Patient Care Experience for Undergraduate Pharmacy Students. *American Journal of Pharmaceutical Education*, **77 (8)**: Article 173.
42. Basheti IA, Qunaibi EA, Hamadi SA, Abu-Gharbieh E, Saleh S, AbuRuz S, Mohamoud M, **Bulatova NR** (2014). Patient Perspectives of the Role of the Community Pharmacist in the Middle East: Jordan, United Arab Emirates and Iraq. *Pharmacology & Pharmacy*, **5(6)**: 588-599.
43. Madae'en SS, **Bulatova NR**, Al-Qhewii A, Sakran LH, El-Zayyat HH, Abu Kamar MK, Al-Haqeesh HS, Younes AM (2014). Stroke Awareness in the General Population: A Study from Jordan. *Tropical Journal of Pharmaceutical Research*, **12(6)**:1071-1076.
44. Al-Diab O, Yousef A-M, Al Manassrah E, Masadeh A, Olemat M, Qosa H,

- Kherbash A, **Bulatova NR** (2015). Genotype and Haplotype Analysis of ABCB1 at 1236, 2677 and 3435 among Jordanian Population. *Tropical Journal of Pharmaceutical Research*, 14(6):1013-1013.
45. Jaber D, **Bulatova N**, Suyagh M, Yousef A-M, Wazaiify M (2015). Knowledge, Attitude and Opinion of Drug Misuse and Abuse by Pharmacy Students: A Cross-Sectional Study in Jordan. *Tropical Journal of Pharmaceutical Research*, 14(8):1501-1508.
46. Elayeh E, **Bulatova N**, Basheti I, Abu Farha R, Al-Rawi N, Abu Snaineh A, Alahwal I. (2016). The Use and Safety of Medications Known to Affect Driving in Jordan: a Cross-sectional Study. *Traffic Injury Prevention*. 17:3, 238-244.
47. Akour A, Kasabri V, Afifi F, **Bulatova N**. (2016). The Use of Medicinal Herbs in Gynecological and Pregnancy-Related Disorders by Jordanian Women: A Review of Folkloric Practice vs. Evidence-Based Pharmacology. *Pharmaceutical Biology*, Feb 25:1-18.
48. Abuhaliema AM, Yousef A-MF, **Bulatova NR**, ElMadany NN, Awwad NM, Yousef MA, El-Majdalawi KZ. (2016). Influence of genotype and haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the incidence of breast cancer. Case-control study. *Asian Pacific Journal of Cancer Prevention*, 17(1):261-6.
49. Amrani I, **Bulatova N**, Awidi A, Yousef A-M, Almasad J, Al-Masri M, Abu Tahoun L. (2016). Lack of association between CYP1A1 M2 and M4 Polymorphisms and Breast Carcinoma in Jordanian Women: A Case-Control Study. *Asian Pacific Journal of Cancer Prevention*, 17(1):387-93.
50. Basheti IA, Al-Qudah RA, Obeidat NM, **Bulatova NR** (2016). Home medication management review in outpatients with chronic diseases in Jordan: a randomized control trial. *Int J Clin Pharm*, 38:404–413.
51. Akour AA, Kasabri VN, **Bulatova N**, Bustanji Y, Momani M, Zayed A, Al-Nuoaimi M,

Fahmawi H, Al-Selawi R (2016). Elevated Serum Levels of Pro-inflammatory Markers are Associated with Glucose Intolerance in Metabolic Syndrome Patients from Jordan. *Jordan Medical Journal*. 50 (4), 169-176.

52. Yousef A-M, Qosa H, **Bulatova N**, Abuhaliema A, Almadhoun H, Khayyat G, Olemat M (2016). Effects of genetic polymorphism in CYP3A4 and CYP3A5 genes on tacrolimus dose among kidney transplant recipients. *Iran J Kidney Dis*. 10 (3), 156-63.

53. Almuqdadi A, **Bulatova N**, Yousef A-M (2016). The effect of atypical antipsychotics on platelet aggregation. *Open Journal of Hematology*. 7 (1).

54. Basheti IA, Saqf El Hait S, Qunaibi EA, Aburuz S, **Bulatova N** (2016). Associations between patient factors and medication adherence: a Jordanian experience. *Pharmacy Practice (Granada)*. 14 (1), 0-0.

55. Al-Rawashdeh A, Kasabri V, **Bulatova N**, Akour A, Zayed A, Momani M, Khawaja N, Bustanji H, Hyasat D (2017). The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 11 (1), 59-67.

56. Kahwaji, R., Kasabri, V., **Bulatova, N.**, Akour A, Bustanji H, Khawaja N, Hyasat D, Zayed A, Momani M, Bustanji Y, AlHiari Y, Mashallah, S., Al-Nouaaيمي, M (2017). Evaluation of correlations of Plasma Levels of Oxytocin, Omentin-1 and Irisin in Diabetic and Non-Diabetic Metabolic Syndrome Patients: A Cross Sectional Study in Jordan. *Jordan Medical Journal*. 51 (3), 97-108.

57. Akour A, Farha RA, Alefishat E, Kasabri V, **Bulatova N**, Naffa R (2017). Insulin resistance and levels of cardiovascular biomarkers in night-shift workers. *Sleep and Biological Rhythms*. 15 (4), 283-290.

58. **Bulatova N**, Kasabri V, Qotineh A, Taiba ALA, Yousef A-M, AbuRuz S, Zayed A,

Momani M (2017). Effect of Metformin Combined With Life Style Modification versus Life Style Modification Alone on Proinflammatory-Oxidative Status in Drug Naïve Pre-Diabetic and Diabetic Patients: A Randomized Controlled Study. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 12 (3), 257-267.

59. Akour A, Kasabri V, **Bulatova N**, Bustanji Y, Naffa R, Hyasat D, Khawaja N, Bustanji H, Zayed A, Momani M (2017). Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. *Acta Diabetologica* 54(2), 163-170.

60. Basheti I, Rezeq M, **Bulatova N** (2018). Home medication management review in outpatients with alarming health issues in Jordan: a randomized control trial. *Journal of Pharmaceutical Health Services Research*. 9 (2), 91-100.

61. Al Saudi RM, Kasabri V, Naffa R, **Bulatova N**, Bustanj Y (2018). Glycated LDL-C and glycated HDL-C in association with adiposity, blood and atherogenicity indices in metabolic syndrome patients with and without prediabetes. *Therapeutic Advances in Endocrinology and Metabolism*, 9(10), 311-323.

62. Al-Qudah RA, **Bulatova NR**, Obeidat NM, Basheti IA (2018). Impact of home medication management review on medication adherence among Jordanian patients *Journal of Pharmaceutical Health Services Research* 9 (3), 227-235.

63. Rkhaya SA, **Bulatova N**, Kasabri V, Naffa R, Alquoqa R (2018). Increased malondialdehyde vs. reduced sirtuin 1 in relation with adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 12(6):903-909.

64. Alnajjar LM, **Bulatova NR**, Darwish RM (2018). Evaluation of Four Calcium Channel Blockers as Fluconazole Resistance Inhibitors in *Candida glabrata*. *Journal of Global Antimicrobial Resistance*. 14:185-189.

65. Akour A, Kasabri V, **Bulatova N**, Al Muhaisen S, Naffa R, Fahmawi H, Momani

- M, Zayed A, Bustanji Y (2018). Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes. *The Review of Diabetic Studies*. 14 (4), 364-371.
66. Suyagh M, Alefishat E, Farha RA, Akour A, Kasabri V, **Bulatova N** (2018). The Impact of Shift Work-Related Circadian Rhythm Disruption on Inflammatory Biomarkers. *Jordan Journal of Pharmaceutical Sciences*. Vol. 11: 69-78.
67. Tofiq KO, **Bulatova N**, Kasabri V, Suyagh M, Halaseh L, Alalawi S (2018). Increased lipocalin-2 vs reduced oxytocin in relation with adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes. *Bratisl Lek Listy*. 119(12):762-769.
68. AbuZayed R, **Bulatova N**, Kasabri V, Suyagh M, Halaseh L, Alalawi S (2019). Correlates of zinc finger BED domain-containing protein 3 and ghrelin in metabolic syndrome patients with and without prediabetes. *Hormone Molecular Biology and Clinical Investigation* Published Online: 2019-01-22 | DOI: <https://doi.org/10.1515/hmbci-2018-0052>.
69. Abushahla HS, **Bulatova N**, Kasabri V, Naffa R (2019). Correlates of ghrelin and visfatin in metabolic syndrome patients with and without prediabetes. *International Journal of Diabetes in Developing Countries*. 39(1): 82-93.
70. Mugdadi, A, Raqeeq, M; Wazaify M, **Bulatova N**. (2019). The Effect of an Innovative Psychiatry Clerkship on Pharmacy Students Perceptions towards Mental Health and Stigma: A Pilot Intervention Study from Jordan. *Jordan Journal of Pharmaceutical Sciences*. 12(2): 109-123.
71. Al-Musa, K. Kasabri, V., **Bulatova, N.**, , Al-Rawashdeh, A., Khawaja, N., Bustanji, H., Hyasat, D., Zayed, A., Momani, M., Alalawi, S (2019). Correlations of oxytocin, fibroblast growth factor-21 and hepatocyte growth factor in diabetic and non-diabetic metabolic

syndrome patients: A case- control study from Jordan. Jordan Journal of Pharmaceutical Sciences. 12(2):69-89.

Supervision: M.Sc. Projects

1. **Hisham Qosa.** Genetic polymorphisms of the *CYP3A4* and *CYP3A5* genes and their impact on effectiveness of tacrolimus among Jordanian population. Co-supervisor: Dr. Al-Motassem Yousef. Defended in May, 2007.
2. **Deema Hattab.** Physicians' and pharmacists' awareness about warfarin uses, administration, drugs and food interactions: A study at Jordan University Hospital. Defended in July, 2007.
3. **Mervat Al-Sous.** The impact of patients' education about warfarin on improvement of their basal knowledge regarding its administration and side effects: A study on patients who receive warfarin at Jordan University Hospital. Defended in August, 2007.
4. **Lamy Hamzeh.** Management of dyslipidemia in adult diabetic and nondiabetic patients in Jordan. Defended in May, 2008.
5. **Enas Al-Manassrah.** The effect of genetic polymorphism in the *MDR1* gene on the cyclosporine blood concentration in Jordanian renal transplant patients. Co-supervisor: Dr. Al-Motassem Yousef. Defended in December, 2008.
6. **Ghada Al-Khayyat.** The impact of donors' genotype on tacrolimus pharmacokinetics among kidney transplant patients in Jordanian population. Co-supervisor: Dr. Al-Motassem Yousef. Defended in December, 2008.
7. **Rawan Zmeili.** The effect of genetic polymorphism of *CYP3A5* on the clopidogrel carboxylate pharmacokinetics. Co-supervisor: Dr. Al-Motassem Yousef. Defended in December, 2008.
8. **Muhammad A. Al-Ulemat.** Impact of genetic polymorphism of *ABCB1 (MDR1) G2677T/A* in kidney donors on tacrolimus level in Jordanian kidney transplant recipients. Co-supervisor: Dr. Al-Motassem Yousef. Defended in August, 2010.
9. **Sawsan Abed AL-Aziz AL-Borno.** Evaluation of factors predictive of quality of coronary artery disease in patients undergoing percutaneous coronary angiography (PCA). Co-supervisor: Dr. Al-Motassem Yousef. Defended in August, 2010.
10. **Attallah Abu-Oliem.** A prospective randomized controlled trial to investigate the impact of a clinical pharmacist on treatment-related problems in patients who receive anti-infective therapy in the general intensive care unit (ICU) ward of a major medical

center in Jordan. Principal supervisor: Dr. Amal Al-Bakri, second co-supervisor: Dr. Hussein Shalan (Head, ICU Department, King Hussein Medical City, Amman, Jordan). Defended in December, 2010.

11. Amina Yousef. Genetic polymorphism of vitamin D receptor at *rs7975232* and prevalence of asthma among Jordanians: cross-sectional observational study. Principal supervisor: Dr. Al-Motassem Yousef, second co-supervisor Dr. Iman Basheti (the Applied Sciences Private University, Amman, Jordan). Defended in April, 2011.

12. Iman Amrani. Association of *M2* polymorphism in *CYP1A1* with breast carcinoma in Jordanian women: a cross-sectional observational study. Co-supervisor: Prof. Abdallah Abbadi (Faculty of Medicine). Defended in April, 2011.

13. Ahmed Masadeh. Impact of genetic polymorphism of *ABCB1 (MDR1) 2677G>T – A* in kidney donors on tacrolimus level in Jordanian kidney transplant recipients during the early posttransplantation period. Co-supervisor: Dr. Al-Motassem Yousef. Defended in June, 2011.

14. Mohammed Dweib. Impact of clinical pharmacist's intervention on health outcomes in patients with diabetes mellitus. Co-supervisors: Dr. Salah Abu Ruz & Dr. Ayman Aref (Faculty of Medicine). Defended in June, 2011.

15. Leena Abdul Al. A study of treatment related problems associated with metabolic complications in chronic kidney disease patients who receive hemodialysis. Co-supervisors: Dr. Al-Motassem Yousef and Dr. Izzat Alawwa (Faculty of Medicine). Defended in May, 2012.

16. Ali Al-Migdadi. The in vitro effect of antipsychotics on platelet aggregation. Defended in December 2013.

17. Alaa Abu Oodeh. Association of genetic polymorphism of tumor necrosis factor and vitiligo. Co-supervisor: Dr. Al-Motassem Yousef. Defended in in May 2014.

18. Tareq Al-Ghazzawi. Appropriateness of the Preparation and Administration of Intravenous Medications in the Pediatric Intensive Care Unit (ICU) at Palestine Medical Complex. Co-supervisor: Dr. Al-Motassem Yousef. Defended in December 2013.

19. Reham Doodeen. The effect of smoking on the activity of ticagrelor among Jordanians. Defended in December 2013.

20. **Dana Jarrar**. The effect of smoking on the activity of the antiplatelet agent tirofiban among Jordanians. Defended in December 2013.

21. **Ali Al-Muqdadi**. The in vitro effect of antipsychotics on platelet aggregation. Defended in January 2014.

22. **Amenah Qotineh**. The effect of metformin and life style modification versus life style modification alone on oxidation status in prediabetic and pharmacotherapy-naïve diabetic patients. Co-supervisor: Dr. Violet Kasabri. Defended in May 2014.

23. **Amani Faisal AlRawashdeh**. The association between serum levels of oxytocin (OXT) and betatrophin in type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MS) in Jordan: A cross-sectional study. Principal supervisor: Dr. Violet Kasabri. Defended in April 2015.

24. **Amal AbuHannoud**. The association between serum levels of oxytocin (OXT) and endothelin-1 and nesfatin in type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MS) in Jordan: A cross-sectional study. Co-supervisor: Dr. Violet Kasabri. Defended in April 2015.

25. **Khaled AlMousa**. The association between serum levels of oxytocin (OXT) and Fibroblast Growth factor -21 and Hepatocyte Growth Factor in type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MS) in Jordan: A cross-sectional study. Principal supervisor: Dr. Violet Kasabri. Defended in April 2015.

26. **Rama Kahwaji**. The association between serum levels of oxytocin (OXT) and irisin in type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MS) in Jordan: A cross-sectional study. Co-supervisor: Dr. Violet Kasabri. Defended in July 2015.

27. **Mai Rezeq**. Home medication management review in outpatients with chronic diseases in Jordan via community pharmacy: an interventional study. Co-supervisor: Dr. Iman Basheti (the Applied Sciences Private University, Amman, Jordan). Defended in April 2015.

28. **Rajaa Alqudah**. Home medication management review in outpatients with chronic diseases in Jordan via hospital based pharmacy: an interventional study. Co-supervisor: Dr. Iman Basheti (the Applied Sciences Private University, Amman, Jordan). Defended in April 2015.

29. **Ali Abuhalimeh**. The relation between genetic polymorphism of MDR1 gene

C3435T (rs1045642) and incidence of breast cancer among Jordanian patients, Case control study. Co-supervisor: Prof. Al-Motassem Yousef. Defended in June 2015.

30. **Ethar Omar**. The association of genetic polymorphism of catalase (-262Cytosine>Thymine) gene with the susceptibility to vitiligo among Jordanians. Case control study. Defended in August 2015.

31. **Lina Al-Najjar**. Study of chemosensitizing effect of calcium channel blockers in fluconazole-resistant strains of *Candida glabrata*. Co-supervisor: Prof. Rula Darwish. Defended in August 2016.

32. **Heeba Abu Shahla**. Study of plasma levels of ghrelin and visfatin and correlation between them in diabetic and non-diabetic patients with metabolic syndrome: A cross-sectional study in Jordan. Defended in December 2016.

32. **Hayya Yaseen**. The role of clinical pharmacist in the treatment of drug abuse: a randomized control trial. Co-supervisor: Prof. Mayyada Wazaify. Defended in November, 2017.

33. **Bashar Alhalifa**. Study of the synergistic effect of selective serotonin reuptake inhibitors with fluconazole against resistant strains of *Candida glabrata*. Co-supervisor: Prof. Rula Darwish. Defended in May 2018.

34. **Kashma Aziz**. A cross-sectional study of oxytocin and lipocalin plasma levels and their correlations with a set of clinical parameters in normoglycemic and hyperglycemic patients with metabolic syndrome in Jordan. Principal supervisor: Prof. Violet Kasabri. Defended in April 2018.

35. **Abdul Rahman Farhan**. A cross-sectional study of visfatin and klotho plasma levels and their correlations with a set of clinical parameters in normoglycemic and hyperglycemic patients with metabolic syndrome in Jordan. Defended in May, 2018.

36. **Waed AbuRuqba**. Study of the effect of proton pump inhibitors on fluconazole-resistant strains of *Candida glabrata*. Defended in June 2018. Co-supervisor: Prof. Rula Darwish.

37. Rawan Abu Zayed. A cross-sectional study of ghrelin and zinc-finger bed domain-containing protein 3 plasma levels and their correlations with a set of clinical parameters in normoglycemic and hyperglycemic patients with metabolic syndrome in Jordan. Principal supervisor: Prof. Violet Kasabri. Defended in June, 2018.

38. **Tareq Hamida**. Alteration in the expression of the cancer resistance-related gene in response to chronic hypoxia in pancreatic cancer. Co-supervisor: Dr. Malek Zuhlif

(School of Medicine). Defended in June 2018.

39. **Hala Halifeh**. The impact of clinical pharmacist intervention on plasma levels of betatrophin and IL-10 in pregnancy hyperglycemia management. Defended in December, 2018.

40. **Waseem Agha**. A cross-sectional study of omentin and leptin plasma levels and their correlations with a set of clinical parameters in normoglycemic and hyperglycemic patients with metabolic syndrome in Jordan. Principal supervisor: Prof. Violet kasabri. Defended in December, 2018.

A member in the MSc/PhD examination committees

1. Comprehensive study of the use of prophylactic antibiotics in clinical practice in cardiac surgery in Jordan: microbiological study of normal flora and surgical site infecting organism, adherence to international guidelines, and obstacles against adherence (July, 2007).
2. Investigation of factors affecting blood pressure and quality of life in out-patients with hypertension: focus on drug related problems (July, 2007).
3. The assessment of the anti-adhesive and anti-biofilm activities of selected agents towards the establishment of pseudo steady-state microbial biofilms on abiotic surfaces and their potential use as catheter lock therapy (March, 2008).
4. Perceived barriers to participating in continuing education: the views of registered clinical pharmacists in Jordan (2008).
5. Pharmaceutical care in hospitalized pediatric patients: a randomized controlled trial (May, 2009).
6. Comparative study of the biological potency of recombinant human erythropoietin in pharmaceutical products in Jordan (July, 2009).
7. The effect of controlling hyperglycemia on the morbidity and mortality of intensive care unit (ICU) patients (July, 2009).
8. Influence of genetic polymorphism of *ABCB-1* gene at position 3435 on 600 mg Clopidogrel Pharmacokinetics as measured by serum level of

- Carboxylic acid metabolite (August, 2009).
9. The influence of genetic polymorphism of *CYP3A5**1/*3 and *6 on tacrolimus serum concentration among Jordanian liver transplant patients (January, 2010).
 10. Aspirin resistance among Jordanian population (July, 2010).
 11. Promotion of appropriate knowledge and attitude towards medicines among school children and the role of teachers (August, 2010).
 12. Comprehensive pharmaceutical care program for patients taking multiple medications at community pharmacy settings (May, 2011).
 13. Association between the polymorphism of *DENND1B* gene at *rs2786098* on susceptibility to asthma among adult Jordanians (January, 2012).
 14. Evaluation of tempol effects on DNA damage induced by vorinostst. (July, 2012) – **at Jordan University of Science and Technology.**
 15. Studying the effect of specific wave length light activation on photosensitizer-pluronic based topical formula against *Staphylococcus aureus* culture (May, 2012).
 16. The role of clinical pharmacist in the control of blood sugar in diabetic patients during the month of Ramadan. July, 2012.
 17. A cross-sectional study of the effects of chronic use of metformin on the serum levels of vitamin B12 in Jordanian patients with type 2 diabetes mellitus. December, 2012.
 18. Epigenetic down-regulation of P14^{ARF} and cyclin A1 in colorectal cancer patients in Jordan. March, 2013- **at Jordan University of Science and Technology.**
 19. A cross-sectional study of prevalence of dyslipidemia in non-obese healthy Jordanian adults. April, 2013.
 20. Evaluation of vitamin B12 effects on DNA damage induced by hydrochlorothiazide. June, 2013- **at Jordan University of Science and Technology.**
 21. Evaluation of the effect of sildenafil on chronic psychosocial stress-induced cognitive impairment. August, 2013- **at Jordan University of Science and Technology.**

22. Variability in response to ticagrelor in patients with diabetes mellitus using ADP as agonist: ex-vivo study. August, 2013.
23. Variability in response to tirofiban among Jordanian diabetics and non-diabetics. August, 2013.
24. Baseline characteristics and response to ticagrelor in Jordanian patients with acute coronary syndrome: cross sectional study. December 2013.
25. PLATINUM ANTINEOPLASTIC AGENTS-INDUCED LONG-TERM HEARING IMPAIRMENT AND ITS ASSOCIATION WITH GLUTATHIONE S-TRANSFERASE P1 (GSTP1) GENETIC POLYMORPHISM AT (RS1695) AMONG JORDANIAN PEOPLE WITH CANCER: CASE-CONTROL STUDY. December, 2013.
26. Development of (Diaba-Tec) program and validation of its insulin titration part in type 2 diabetic patients in hospital general medical-surgical ward who are eating normal diet. December, 2013.
27. Synthesis and pharmacological evaluation of some 5-arylkyl-2-amino-1,3,4-thiadiazoles. January, 2014 – **at Al Ahliyya Amman University.**
28. Platinum antineoplastic agents-induced long-term hearing impairment and its association with glutathione S-transferase P1 (GSTP1) genetic polymorphism at (RS1695) among Jordanian people with cancer: case-control study. January, 2014.
29. Cytotoxic activity against prostate cancer cell line and antibacterial action of peptides from the venom of *Androctonus crassicauda*. May, 2014 - **at Al Ahliyya Amman University.**
30. Cross sectional evaluation of the usage of the Broad spectrum intravenous antibiotics in the JUH intensive care units. May, 2014.
31. The cytotoxic effect of the extract of *Anchusa strigosa* (Him Him) grown in Jordan against different cancer cell lines. June, 2014 – **at Al Ahliyya Amman University.**
32. Study of potential cytotoxicity of *Myrtus communis* L. berries and flowers extracts grown in Jordan against different cancer cell lines. June, 2014 – **at Al Ahliyya Amman University.**
33. Evaluation of venous thromboembolism (VTE) prophylaxis in the Jordan University Hospital, appropriateness and cost effectiveness, and the role of the

- clinical pharmacist in appropriate VTE prophylaxis. June, 2014.
34. Abuse and misuse of prescription and non-prescription drugs – a qualitative and quantitative experience from community pharmacies in Aden city – Yemen. July, 2014.
 35. Genetic polymorphism of (6-BP INS/DEL in 3'-UTR) of the thymidylate synthetase gene and response to antimetabolites-based chemotherapy in patients with colorectal cancer. December 2014.
 36. Allele and genotype frequencies of methylenetetrahydrofolate reductase C677T (Rs1801133) polymorphism among Jordanian lung cancer patients: case control study. December 2014.
 37. Allelic and genotype frequencies of the polymorphic thymidylate synthase ((6Bp Deletion/Insertion polymorphism in the TS 3'
 38. Genetic polymorphism of the tandem repeats in the 5'-UTR enhancer region of the thymidylate synthetase gene and response to 5-fluorouracil and capecitabine in patients with colorectal cancer. March 2015.
 39. The relationship between genetic polymorphism in methylenetetrahydrofolate reductase C677T, RS no. 1801133 and the incidence of breast cancer among Jordanian patients. Case control study. March 2015.
 40. Assessment of the clinical and cost-impact of clinical pharmacist-initiated interventions in cardiovascular hospitalized patients. April 2015.
 41. Evaluation of correlation between oxytocin (OXT) plasma levels and metabolic syndrome (MS) biomarkers (endothelin-1 and nesfatin) in diabetic and non-diabetic metabolic syndrome patients in Jordan. April, 2015.
 42. Assessment of the clinical and cost-impact of clinical pharmacist-initiated interventions in hospitalized patients with cardiovascular diseases. April 2017.
 43. Anemia in diabetic foot patients at Jordan University Hospital. May 2015.
 44. Evaluation for the efficacy & safety of aspirin as venous thromboembolic (VTE) prophylactic agent after major orthopaedic surgeries in Jordan University Hospital. May 2015.
 45. Genetic tandem repeat polymorphism in the 5'-UTR enhancer region of the thymidylate synthetase gene and response to 5-fluorouracil and capecitabine in patients with colorectal cancer. May 2015.
 46. A cross sectional study of the use of Methylphenidate in children with suspected

- or confirmed diagnosis of attention deficit hyperactivity disorder in a sample of the Jordanian population. May 2015.
47. Prevalence of prescription and non-prescription drug-related overdoses at Emergency departments in Amman – a cross-sectional study. May 2015.
 48. Assessment of immunomodulatory effects of tigecycline in Balb/c mice. July 2015.
 49. Genetic polymorphism in Methylene tetra hydrofolate reductase MTHFR Cytosine 677 thymine (re 1801133), and response to 5 fluorouracil and capecitabine in patients with colorectal cancer among Jordanian population. August 2015.
 50. Phytochemical screening and evaluation of antioxidant, antimicrobial and antiproliferative (against breast cancer cell line T47D) activities of the leaves of *Elaeagnus angustifolia* grown in Jordan. August 2015.
 51. Study of the correlation between plasma levels of glycated-LDL and glycated-HDL in diabetic and non-diabetic patients with metabolic syndrome (MetS): a cross-sectional study in Jordan. December 2016.
 52. Evaluating the protective effect of tempol on memory and cognitive impairment induced by posttraumatic stress disorder. December 2016 – **at Jordan University of Science and Technology.**
 53. Evaluation of the effect of melatonin on learning and memory impairment induced by high-fat high carbohydrates diet in rats. December 2016 - **at Jordan University of Science and Technology.**
 54. Evaluation of the effect of melatonin on learning and memory impairment induced by high-fat high carbohydrates diet in rats. December 2016 - **at Jordan University of Science and Technology.**
 55. Evaluation of the effect of etazolol on the DNA of human cultured lymphocytes. December 2016 - **at Jordan University of Science and Technology.**
 56. Study of the correlation between plasma levels of malonaldehyde and sirtuin 1 in diabetic and non-diabetic patients with metabolic syndrome: a cross-sectional study in Jordan. February 2017.
 57. Role of clinical pharmacist in the management of hyperglycemia during pregnancy. March 2017.
 58. Genetic polymorphism in DPYD M166V (rs2297595) and response to 5-

fluorouracil and capecitabine-based chemotherapy in Jordanian patients with colorectal cancer. May 2017.

59. Pharmacist-Directed Medication Reconciliation Service for Reducing Discrepancies among Medically Hospitalized Patients in Jordan; a Randomized Control Trial. December 2017 – **at Applied Sciences Private University, Amman, Jordan.**
60. Role of Pharmacist in Reducing Inappropriate Use of Therapeutic Antimicrobials in Surgical Ward. December 2017.
61. Anti-pancreatic Lipase and Anti-proliferative Activities of New Fluoroquinolones. December, 2017.
62. Exploring the Value of a Pharmacist-Directed Medication Reconciliation Service for Reducing Medication Discrepancies for Hospitalized Patients in Jordan: a Randomized Controlled Trial. December, 2017 - **at Applied Sciences Private University, Amman, Jordan.**
63. Genetic polymorphisms of MTHFR 677C>T and 1289A>C and methotrexate toxicity in patients with acute lymphoblastic anemia in Jordan. December, 2017.
64. Genetic polymorphism of dihydrofolate reductase 19-base pair deletion (RS70991108), and the toxicity of methotrexate in acute lymphoblastic leukemia (ALL) in Jordan: a cross-sectional observational study. March, 2018.

PhD Defences:

1. Phytochemical and pharmacological screening of wild *Papaver polytrichum* BOISS ET KOTSCHY/*Papaver Rhoeas* L. and attempting chemical modification/partial synthesis of some model compounds January, 2012.

Conferences and Talks Attended

1. All-Union Pharmacological Congress (1987), Tashkent, Uzbekistan (USSR).
2. All-Union School of Young Scientists in Immunopharmacology (1988), Chelyabinsk, Russia (USSR)
3. All-Union School of Young Medical Scientists (1989), Ufa, Russia

- (USSR)
4. The First International Conference in Clinical Pharmacy-Future and Challenge **(1998)** Amman, Jordan.
 5. The Introduction of the Course in Environmental Health **(1999)** WHO Office, Amman, Jordan.
 6. Extending the Therapeutic Options in Epilepsy **(2000)** Lisboa, Portugal.
 7. The 5th Scientific Congress of the Association of the Colleges of Pharmacy in the Arab World & the 2nd International Conference of the Faculty of Pharmacy **(October 16-18, 2001)**, Amman.
 8. The Third Jordanian Neurosciences Society Conference **(October, 2001)** Amman, Jordan.
 9. Faculty of Pharmacy Symposium "Advanced Computer Aided Drug Discovery Techniques Adopted at the Faculty of Pharmacy-The University of Jordan" **(2003)**. Amman, Jordan.
 10. First International Congress of the Emirates Neurology Society (EMINS) and Fifth GCC Neurology Symposium **(March, 6-9, 2006)**, Dubai, UAE.
 11. The 3rd International Conference of the Royal Medical Services in Collaboration with the Royal College of Physicians of London **(2006)**. Amman, Jordan.
 12. USP 2nd Regional Scientific Workshop **(9-10, September, 2006)**. Amman, Jordan.
 13. Neuromediterranee VIII Congress **(November, 2-5, 2006)**. Dead Sea, Jordan
 14. The 9th Jordanian Conference of Internal Medicine **(October, 20-23, 2008)**. Amman, Jordan.
 15. Triple Neuroscience Standalone EGM **(May, 23-25, 2009)**. Moscow, Russia.
 16. Middle East Epilepsy and Neurology Update Meeting **(October, 17-19, 2010)**. Beirut, Lebanon.
 17. The Second Congress for the Jordanian Society of Russian-Speaking Physicians **(November, 2010)** Amman, Jordan
 18. The 6th International Congress of the Jordanian Neurological Society, The

3rd Congress of the Jordanian Chapter of Epilepsy (**October, 2015**).

Amman, Jordan.

19. The 7th International Congress of the Jordanian Neurological Society, The
5th Congress of the Jordanian Chapter of Epilepsy (**September, 2017**).

Amman, Jordan.

20.

Conferences: Podium Presentations

1. **Bulatova NR (1985)**. The effect of adamantyl derivatives on humoral immune response. Conference on Sulfoorganic Compounds in Medicine. Riga, Latvia (USSR).
2. **Bulatova NR (1986)**. The effect of pyrimidines on the primary immune response. Scientific Conference of Bashkir Medical Institute, Ufa, Russia, (USSR).
3. **Bulatova NR, Krinskaya AV, Valdman AV (1989)**. Effect of pyrimidines, tuftsin and its derivatives on mononuclear phagocytes and brain synaptosomal membranes in stress. Scientific Conference of Scientific- Research Institute of Pharmacology, Moscow, Russia (USSR).
4. Ibrahim ZZ, Phaily SS, **B(o)ulatova N (October 2001)**. The effect of *Ferula hermonis* extract on blood glucose and lipid levels in mice. The International Conference of Colleges of Pharmacy of Arabic World. Amman, Jordan.
5. **Bulatova NR, Darwish RM (November 2006)**. The effect of phenothiazines on fluconazole activity against *C. albicans*. The First Congress for the Jordanian Society of Russian-Speaking Physicians. Amman, Jordan.
6. **Bulatova N, Yousef A-M, Al-Khayyat G, Qosa H (February, 2011)**. Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors. Third Kuwait International Pharmacy Conference, Al Kuwait, Kuwait.
7. Basheti I, Qunaibi E, **Bulatova N, Samara S, AbuRuz S (September, 2011)**. Exploring the need and feasibility for conducting medication management review by community pharmacists in Jordan. Royal Pharmaceutical Society Conference, London, UK.
8. **Bulatova NR, Abdul Al L, Yousef A-M, Alawwa I (October, 2012)**. Metabolic complications in Jordanian chronic kidney disease patients who receive hemodialysis. The 15th Scientific Congress of the Association of Pharmacy Colleges in the Arab World & The 3rd International Conference of the Faculty of Pharmacy / The University of Jordan.
9. **Bulatova NR**. Management of hypertension in different categories of patients (ischemic heart disease, diabetes mellitus, chronic kidney disease). Conference “Relevant Issues of Prevention, Treatment and Rehabilitation of Patients with Cardiovascular Diseases”. Ufa, Russia, December, 2015.

10. **Bulatova NR.** An Innovative Geriatric-Psychiatric Rotation: Example of Pharmacist Inter-professional Collaboration. The ASU-Second International Medical Conference. Quality Use of Medicines and Patient Care: An Inter-Professional Approach. Amman, 12-13 March, 2016.
11. **Bulatova N.** Clinical aspects of biosimilars. At the Training Workshop “Shifting Towards Biotech Pharmaceuticals” organized by MONOJO jointly with the International Labor Organization. Amman, Landmark Hotel, March, 2016.
12. Al Muhaisen S, Akour A, Kasabri V, **Bulatova N**, Naffa R, Fahmawi H, Momani M, Zayed A, Bustanji Y. Association of oxytocin with glucose intolerance and inflammation biomarkers in metabolic syndrome patients with and without prediabetes. 8th Annual Conference on Clinical Research & Biomarkers. Prague, Czech Republic July 19 - 20, 2018.
13. Kasabri V, Akour A, **Boulatova N**, Bustanji Y, Naffa R, Hyasat D, Khawaja N, Zayed A, Momani M. Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients. The impact of shift work related circadian rhythm disruption in lean subjects on inflammation biomarkers. Prague, Czech Republic July 19 - 20, 2018.
14. Suyagh M, Akour A, Alefishat E, Abu Farha R, Kasabri V, **Bulatova N**. The impact of shift work related circadian rhythm disruption in lean subjects on inflammation biomarkers. Prague, Czech Republic July 19 - 20, 2018.
15. **Bulatova N**, Altaher N, BaniMustafa RA, Al-Saleh A, Yasin H, Zawiah M, Khalefah HN, Ghilan MA, Al-Lahham AJ, Hudaib MI, Younes S, AlKhawaldeh B. Prevalence of QTc prolongation among patients with mental illnesses in Jordan: a cross-sectional study. The 5th International Jordanian Psychiatric Conference. Amman, Le Royal Hotel, October 25-27, 2018.

Conferences: Poster Presentations

1. Qato MK, **B(o)ulatova NR**, Ibrahim ZZ (1999). Effect of plants used in Arabic folkloric medicine on blood glucose, cholesterol and triglycerides levels in diabetic mice. FASEB Meeting, Washington, DC, USA.
2. Basheti IA, Qunaibi EA, **Bulatova NR** (August 2010). Identification of treatment related problems for outpatients with chronic diseases through community pharmacy: A study from Jordan. The 16th International Social Pharmacy Workshop conference, Lisboa, Portugal.
3. AbuRuz S, **Bulatova N**, Yousef AM, Al-Gazawi MA (August 2010). Comprehensive prospective assessment for treatment related problems in hospitalized internal medicine patients. The 16th International Social Pharmacy Workshop conference, Lisboa, Portugal.
4. Al-Bakri AG, Shalan H, Abu-oliem A, **Bulatova N** (April 2011). A Prospective randomized controlled trial to investigate the impact of a clinical pharmacist on treatment-related problems in patients who receive anti-infective therapy in the general intensive care unit (ICU) ward of a major medical center in Jordan. Faculty of Pharmacy/UJ Scientific Day. Amman-Jordan.
5. Amrani I, **Bulatova N**, Abbadi AA, Massad J, Yousef A-M, Al-Masri M, Abu Tahoun L (2011). Association between M2 polymorphism in CYP1A1 and breast carcinoma among Jordanian women: a case control study. Faculty of Pharmacy/UJ Scientific Day. Amman-Jordan.
6. Yassin H, **Bulatova NR**, Anani J, Wazaify M (2017). The role of a clinical pharmacist in the treatment of drug abuse: a randomized control trial. Applied Science University Pharmacy Third Conference “Recent Trends in Postgraduate Research”. Applied Sciences University, Amman, Jordan. April 2017.
7. Abu Rkhaya S, **Bulatova N**, Kasabri V, Akour A, Naffa R (2017). The

correlation between plasma levels of malonaldehyde and sirtuin 1 in newly diagnosed pre/diabetic patients with metabolic syndrome. Applied Science University Pharmacy Third Conference “Recent Trends in Postgraduate Research”. Applied Sciences University, Amman, Jordan. April 2017.

8. Al Saudi R, Kasabri V, Akour A, **Bulatova N**, Naffa R, Bustanji Y (2017). Levels of glycated-LDL-C and glycated-HDL-C in drug-naïve diabetic and non-diabetic patients with metabolic syndrome. Applied Science University Pharmacy Third Conference “Recent Trends in Postgraduate Research”. Applied Sciences University, Amman, Jordan. April 2017.
9. **Bulatova N**, Elayeh E, Abdullah S, Halaseh L (2018). Assessment of Inappropriate Medication Use in Jordanian Elderly Patients at Medical Wards by Beers 2015 Criteria. 34th World Congress of Internal Medicine. Cape Town, South Africa. 18-21 October 2018.

Workshops and Training Courses Attended

1. Teaching and Assessment Methods. **(2-December-24 January, 2003)**. Centre for Educational Development. Amman, Jordan.
2. Managing Multiple Choice Questions. **(3. June, 2003)**. Centre for Educational Development. Amman, Jordan.
3. Training Trainers for Tempus and other Programmes **(July, 2005)**. The consortium of Universita Cattolica del Sacro Cuore Milan, Erasmus Hogeschool Brussel, European cultural interactions Athens and the University of Jordan. Supported by the European Commission DG EAC, within the Tempus-Meda project *SCM M007A04*. Amman, Jordan.
4. Training course on using Blackboard **(2005)**. King Abdulla II School for Information and Technology Amman, Jordan.
5. Real Time PCR Principle and Applications **(28 January-8 February, 2007)**. The Center of Consultation, University of Jordan, Amman, Jordan.
6. Human Participants Protection Education for Research Team online course **(14 October, 2010)**. National Cancer Institute, U.S. National Institutes of Health.
7. Training course on using Moodle (e-learning) **(September 2013)**. Al-Horani e-learning center, Amman Alahliyya University, Amman, Jordan.
8. Workshop in Clinical Pharmacy, Jordanian Pharmaceutical Association (December, 2011) Amman, Jordan.
9. Workshop on Intended Learning Outcomes. Quality Assurance Center, The University of Jordan **(November, 2015)**, Amman, Jordan.
10. Matching Course ILOs to Program ILOs in Course Syllabus Workshop, The School of Pharmacy, The University of Jordan, November, 9, 2017.
11. E-Learning workshop at the School of Pharmacy, The University of Jordan. November, 16, 2017.

Memberships

- 2001-current** Jordan Medical Association, Jordan.
- 2002** Member of Bioequivalence Committee at Jordan FDA
- 2008-2010** Member of Committee for Scientific Awards at ACDIMA Company
- 2010-till now** Member of DAAD Committee for selection of Jordanian candidates for doctorate studies in Germany
- 2001-current** Member at a number of University and Faculty committees, e.g. Scientific research committee, Library committee, Equipment and laboratory committee, Sports committee.....etc).
- 2012** Member of the Executive Committee for the preparation of the International Conference of Faculties of Pharmacy, Head of the Committee for the Clinical Skills Competition during the Conference
- 2013-2014** Head of the Committee for the Bachelor in Pharmacy & Masters in Pharmaceutical Sciences Curriculum Development at Al Ahliyya Amman University
- 2012-till now** Member of the World Society Interdisciplinary Anti-Aging Medicine

Computer Skills and Others

1. The University of Jordan Computer Driving License (UJCDL), passing successfully all of its 9 modules. (Introduction, Windows, Word, Excel, PowerPoint, Access, Internet, Outlook, FrontPage).
2. The e-learning course (Moodle)

Referee for manuscripts published within

1. Jordan Journal of Pharmaceutical Sciences
2. Journal of Complementary and Alternative Medicine

Teaching Experience

1. **Undergraduate Pharmacy and PharmD students:** Medical Terminology, Pharmacology 1, Pharmacology 2, Pharmacotherapy 1, Pathophysiology, Pharmacotherapy 2, Pharmacotherapy 3, Pharmacotherapy 4, Non-prescription Drugs, Clinical Pharmacy Practical Course, Training in Clinical Pharmacy (Internal Medicine and Gynecology).
2. **Master in Clinical Pharmacy:** Pharmacotherapy 1, Pharmacotherapy 2, Pharmacotherapy 3, Clinical Pharmacy Training 1, Clinical Pharmacy Training 2, Clinical Pharmacy Training 3 (Specialized), Pharmaceutical Care

Last Updated 20/April /2017

